Monica M Johnson1, Kristy M Ainslie1. 1. Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA.
Abstract
PURPOSE OF REVIEW: Burkholderia pseudomallei's and Burkholderia mallei's high rate of infectivity, limited treatment options, and potential use as biological warfare agents underscore the need for development of effective vaccines against these bacteria. Research efforts focused on vaccines against these bacteria are in pre-clinical stages, with no approved formulations currently on the market. RECENT FINDINGS: Several live attenuated and subunit vaccine formulations have been evaluated in animal studies, with no reports of significant long term survival after lethal challenge. SUMMARY: This review encompasses the most current vaccine strategies to prevent B. pseudomallei and B. mallei infections while providing insight for successful vaccines moving forward.
PURPOSE OF REVIEW: Burkholderia pseudomallei's and Burkholderia mallei's high rate of infectivity, limited treatment options, and potential use as biological warfare agents underscore the need for development of effective vaccines against these bacteria. Research efforts focused on vaccines against these bacteria are in pre-clinical stages, with no approved formulations currently on the market. RECENT FINDINGS: Several live attenuated and subunit vaccine formulations have been evaluated in animal studies, with no reports of significant long term survival after lethal challenge. SUMMARY: This review encompasses the most current vaccine strategies to prevent B. pseudomallei and B. mallei infections while providing insight for successful vaccines moving forward.
Authors: Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici Journal: Clin Vaccine Immunol Date: 2014-03-26
Authors: K L Schully; M G Bell; A M Prouty; M D Gallovic; S Gautam; K J Peine; S Sharma; E M Bachelder; J T Pesce; M A Elberson; K M Ainslie; A Keane-Myers Journal: Int J Pharm Date: 2015-09-28 Impact factor: 5.875
Authors: Michael H Norris; Katie L Propst; Yun Kang; Steven W Dow; Herbert P Schweizer; Tung T Hoang Journal: Infect Immun Date: 2011-08-01 Impact factor: 3.441
Authors: Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball Journal: J Med Microbiol Date: 2004-12 Impact factor: 2.472
Authors: Andrew E Scott; Thomas R Laws; Riccardo V D'Elia; Margaret G M Stokes; Tannistha Nandi; E Diane Williamson; Patrick Tan; Joann L Prior; Timothy P Atkins Journal: Clin Vaccine Immunol Date: 2013-05-15
Authors: J S Friedland; Y Suputtamongkol; D G Remick; W Chaowagul; R M Strieter; S L Kunkel; N J White; G E Griffin Journal: Infect Immun Date: 1992-06 Impact factor: 3.441
Authors: Ashraful Haque; Karen Chu; Anna Easton; Mark P Stevens; Edouard E Galyov; Tim Atkins; Rick Titball; Gregory J Bancroft Journal: J Infect Dis Date: 2006-09-25 Impact factor: 5.226
Authors: Sergei S Biryukov; Christopher K Cote; Christopher P Klimko; Jennifer L Dankmeyer; Nathaniel O Rill; Jennifer L Shoe; Melissa Hunter; Zain Shamsuddin; Ivan Velez; Zander M Hedrick; Raysa Rosario-Acevedo; Yuli Talyansky; Lindsey K Schmidt; Caitlyn E Orne; David P Fetterer; Mary N Burtnick; Paul J Brett; Susan L Welkos; David DeShazer Journal: Front Microbiol Date: 2022-08-17 Impact factor: 6.064